scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1028230999 |
P356 | DOI | 10.1007/S10549-016-3701-7 |
P698 | PubMed publication ID | 26875185 |
P50 | author | Hope Rugo | Q55975497 |
Amy Jo Chien | Q87289244 | ||
Pamela Munster | Q90470925 | ||
Laura Esserman | Q91960202 | ||
Laura J Van't Veer | Q92380286 | ||
Mark M Moasser | Q92502776 | ||
Michelle E Melisko | Q92576217 | ||
Christina Yau | Q114338711 | ||
P2093 | author name string | Andrew H Ko | |
Denise M Wolf | |||
Emmett Schmidt | |||
W Michael Korn | |||
Craig Fancourt | |||
R Katie Kelley | |||
Alyson Cockerill | |||
P2860 | cites work | Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 |
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 | ||
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling | Q27851446 | ||
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
Exploiting the PI3K/AKT pathway for cancer drug discovery | Q29615120 | ||
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers | Q34679149 | ||
Antitumor activity in RAS-driven tumors by blocking AKT and MEK. | Q35103514 | ||
Perturbations of the AKT signaling pathway in human cancer | Q36313181 | ||
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer | Q36476312 | ||
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer | Q37168778 | ||
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer | Q37380424 | ||
Modeling precision treatment of breast cancer | Q37608340 | ||
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors | Q37690991 | ||
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. | Q38944616 | ||
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells | Q39223582 | ||
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer | Q41756399 | ||
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis | Q44259982 | ||
Dose-finding in phase I clinical trials based on toxicity probability intervals. | Q51907391 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | paclitaxel | Q423762 |
trastuzumab | Q412616 | ||
MK-2206 | Q25100065 | ||
P304 | page(s) | 521-530 | |
P577 | publication date | 2016-02-13 | |
P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
P1476 | title | A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies | |
P478 | volume | 155 |
Q64226327 | Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal |
Q52581752 | Current therapeutic landscape for advanced gastroesophageal cancers. |
Q92280905 | Genome atlas analysis based profiling of Akt pathway genes in the early and advanced human prostate cancer |
Q89592800 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial |
Q28072254 | Maximising the potential of AKT inhibitors as anti-cancer treatments |
Q100752660 | Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial |
Q88598954 | Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial |
Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
Q98289829 | Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo |
Q39312902 | The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress |
Q37743486 | mTOR function and therapeutic targeting in breast cancer |
Search more.